{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:33:42Z","timestamp":1790948022190,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003751","name":"Ministerio de Sanidad, Servicios Sociales e Igualdad","doi-asserted-by":"publisher","award":["2009I047"],"award-info":[{"award-number":["2009I047"]}],"id":[{"id":"10.13039\/501100003751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD12\/0028\/0009, RD16\/0017\/0003, RD16\/0017\/0010; PI11\/01961; PI17\/01962; JR16\/00020"],"award-info":[{"award-number":["RD12\/0028\/0009, RD16\/0017\/0003, RD16\/0017\/0010; PI11\/01961; PI17\/01962; JR16\/00020"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HOME\/2014\/JDRU\/AG\/ DRUG\/7082"],"award-info":[{"award-number":["HOME\/2014\/JDRU\/AG\/ DRUG\/7082"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00206","type":"journal-article","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T04:42:29Z","timestamp":1520916149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":60,"title":["Acute Pharmacological Effects of 2C-B in Humans: An Observational Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Esther","family":"Papaseit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mag\u00ed","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"P\u00e9rez-Ma\u00f1\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitona","family":"Pujadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/7854-2016-54","article-title":"Predicting the abuse liability of entactogen-class, new and emerging psychoactive substances via preclinical models of drug self-administration.","volume":"32","author":"Aarde","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/NRL.0b013e3181a3cb53","article-title":"Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion.","volume":"16","author":"Ambrose","year":"2010","journal-title":"Neurologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/hup.2545","article-title":"Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.","volume":"31","author":"Bouso","year":"2016","journal-title":"Hum. Psychopharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/dta.1626","article-title":"The rise of new psychoactive substance use in Australia.","volume":"6","author":"Burns","year":"2014","journal-title":"Drug Test. Anal."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X15666170828162057","article-title":"Correlation between blood and oral fluid psychoactive drug concentrations and cognitive impairment in driving under the influence of drugs.","author":"Busard\u00f2","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.18566\/medupb.v35n2.a08","article-title":"The risk of 2, 5-dimethoxy-4-bromophenylethylamine (2C-B): case.","volume":"35","author":"Caicedo","year":"2016","journal-title":"Med. UPB"},{"key":"B7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jchromb.2004.08.026","article-title":"Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration.","volume":"811","author":"Carmo","year":"2004","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tox.2004.07.004","article-title":"Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human.","volume":"206","author":"Carmo","year":"2005","journal-title":"Toxicology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0269881111431752","article-title":"4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects.","volume":"26","author":"Caudevilla-G\u00e1lligo","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"B10","year":"2013","journal-title":"Ministry of Health and Social Protection (Colombia)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1023\/B:PHAR.0000018600.03664.36","article-title":"A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs.","volume":"26","author":"de Boer","year":"2004","journal-title":"Pharm. World Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/JCP.0b013e31823607f6","article-title":"Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.","volume":"31","author":"Dos Santos","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"B13","year":"2011","journal-title":"Annual Report on the State of the Drugs Problem in Europe."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.euroneuro.2015.05.007","article-title":"Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart.","volume":"25","author":"Farr\u00e9","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.addbeh.2017.11.004","article-title":"Polysubstance use profiles among electronic dance music party attendees in New York City and their relation to use of new psychoactive substances.","volume":"78","author":"Fern\u00e1ndez-Calder\u00f3n","year":"2017","journal-title":"Addict. Behav."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","article-title":"Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.","volume":"35","author":"Glennon","year":"1984","journal-title":"Life Sci."},{"key":"B17","year":"2013"},{"key":"B18","year":"2017"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/643878","article-title":"Acute effects of the novel psychoactive drug 2C-B on emotions.","volume":"2015","author":"Gonz\u00e1lez","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/hup.2323","article-title":"Consumption of new psychoactive substances in a Spanish sample of research chemical users.","volume":"28","author":"Gonz\u00e1lez","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2621","article-title":"Patterns of use and toxicity of new para-halogen substituted cathinones: 4-CMC (clephedrone), 4-CEC (4-chloroethcatinone) and 4-BMC (Brephedrone).","volume":"32","author":"Grifell","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/00005053-196509000-00006","article-title":"Addiction Research Center Inventory (ARCI): development of a general drug estimation scale.","volume":"141","author":"Haertzen","year":"1965","journal-title":"J. Nerv. Ment. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.drugalcdep.2014.11.033","article-title":"Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre.","volume":"147","author":"Hondebrink","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.pnpbp.2010.10.018","article-title":"Persistent psychosis after ingestion of a single tablet of \u20192C-B\u2019.","volume":"35","author":"Huang","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/scan\/nst161","article-title":"MDMA enhances emotional empathy and prosocial behavior.","volume":"9","author":"Hysek","year":"2014","journal-title":"Soc. Cogn. Affect. Neurosci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.drugalcdep.2010.11.005","article-title":"Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.","volume":"115","author":"Johnson","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"B29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/jat\/26.2.61","article-title":"In vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites.","volume":"26","author":"Kanamori","year":"2002","journal-title":"J. Anal. Toxicol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1556-4029.2012.02289.x","article-title":"Analysis of 4-bromo-2,5-dimethoxyphenethylamine abuser\u2019s urine: identification and quantitation of urinary metabolites.","volume":"58","author":"Kanamori","year":"2013","journal-title":"J. Forensic Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.forsciint.2004.04.084","article-title":"A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes.","volume":"148","author":"Kanamori","year":"2005","journal-title":"Forensic Sci. Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/1556-4029.13266","article-title":"Synthesis and analysis of glucuronic acid-conjugated metabolites of 4-Bromo-2,5-dimethoxyphenethylamine.","volume":"62","author":"Kanamori","year":"2017","journal-title":"J. Forensic Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.102.042184","article-title":"Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves.","volume":"304","author":"Kurrasch-Orbaugh","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0376-8716(94)90075-2","article-title":"Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI).","volume":"35","author":"Lamas","year":"1994","journal-title":"Drug Alcohol Depend."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2015.14166","article-title":"Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland.","volume":"145","author":"Liakoni","year":"2015","journal-title":"Swiss Med. Wkly."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.07.012","article-title":"Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs.","author":"Luethi","year":"2017","journal-title":"Neuropharmacology"},{"key":"B37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-3565(24)34877-3","article-title":"Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.","volume":"290","author":"Mas","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1124\/jpet.106.117507","article-title":"Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and5-HT2C receptors.","volume":"321","author":"Moya","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drugalcdep.2015.10.011","article-title":"Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans.","volume":"157","author":"Nugteren-van Lonkhuyzen","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"B40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ajad.12403","article-title":"Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States.","volume":"25","author":"Palamar","year":"2016","journal-title":"Am. J. Addict."},{"key":"B41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/02791072.2017.1320732","article-title":"Something new about something old: a 10-Year follow-up on classical and new psychoactive tryptamines and results of analysis.","volume":"49","author":"Palma-Conesa","year":"2017","journal-title":"J. Psychoactive Drugs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1038\/npp.2016.75","article-title":"Human pharmacology of Mephedrone in comparison with MDMA.","volume":"41","author":"Papaseit","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11419-014-0242-9","article-title":"25B-NBOMe and its precursor 2C-B: modern trends and hidden Dangers.","volume":"33","author":"Papoutsis","year":"2015","journal-title":"Forensic Toxicol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jpba.2007.12.039","article-title":"Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of \u201challucinogenic designer drugs\u201d in urine of consumers.","volume":"47","author":"Pichini","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.drugpo.2016.10.006","article-title":"The hidden web and the fentanyl problem: detection of ocfentanil as an adulterant in heroin.","volume":"40","author":"Quintana","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"B46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000077946","article-title":"Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography.","volume":"50","author":"Riba","year":"2004","journal-title":"Neuropsychobiology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0376-8716(00)00175-7","article-title":"Psychometric assessment of the hallucinogen rating scale.","volume":"62","author":"Riba","year":"","journal-title":"Drug Alcohol Depend."},{"key":"B48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s002130000606","article-title":"Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers.","volume":"154","author":"Riba","year":"","journal-title":"Psychopharmacology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (C drugs).","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000364879","article-title":"Acute effects of 3,4-methylenedioxymethamphetamine and methylphenidate on circulating steroid levels in healthy subjects.","volume":"100","author":"Seibert","year":"2014","journal-title":"Neuroendocrinology"},{"key":"B51","author":"Shulgin","year":"1990","journal-title":"PIHKAL: A Chemical Love Story."},{"key":"B52","first-page":"93","article-title":"Centrally active phenethylamines.","volume":"1","author":"Shulgin","year":"1975","journal-title":"Psychopharmacol. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3109\/15563650.2015.1054502","article-title":"NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System.","volume":"53","author":"Srisuma","year":"2015","journal-title":"Clin. Toxicol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","article-title":"The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.","volume":"189","author":"Tancer","year":"2007","journal-title":"Psychopharmacology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jchromb.2006.08.049","article-title":"Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry.","volume":"846","author":"Theobald","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6848","article-title":"Novel psychoactive substances: types, mechanisms of action, and effects.","volume":"356","author":"Tracy","year":"2017","journal-title":"BMJ"},{"key":"B58","year":"1971","journal-title":"Convention on Psychotropic Substances, 1971."},{"key":"B59","year":"2013","journal-title":"The Challenge of New Psychoactive Substances. 2013."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.bjp.0705722","article-title":"4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes.","volume":"141","author":"Villalobos","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"B61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","article-title":"Brain mechanisms of hallucinogens and entactogens.","volume":"3","author":"Vollenweider","year":"2001","journal-title":"Dialogues Clin. Neurosci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00206\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:01:25Z","timestamp":1751482885000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00206\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":62,"alternative-id":["10.3389\/fphar.2018.00206"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00206","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,13]]},"article-number":"206"}}